LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Начало・Списък с акции・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Затворен

СекторЗдравеопазване

7.93 -0.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.88

Максимум

8.11

Ключови измерители
By Trading Economics
Приходи	-2.7M -24M
Продажби	29M 155M
Марж на печалбата	-15.787
Служители	499
EBITDA	-1M -5.8M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+101.87% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	461M 2.3B
Предишно отваряне	8.81
Предишно затваряне	7.93

Настроения в новините

By Acuity

19%

81%

33 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.925 / 7.38 Подкрепа & съпротива

Amicus Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.09.2025 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17.09.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17.09.2025 г., 21:59 ч. UTC

Печалби

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17.09.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

17.09.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17.09.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17.09.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17.09.2025 г., 21:00 ч. UTC

Печалби

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

17.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.09.2025 г., 19:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 19:59 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17.09.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17.09.2025 г., 18:43 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17.09.2025 г., 18:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17.09.2025 г., 18:20 ч. UTC

Пазарно говорене

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17.09.2025 г., 18:18 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 18:18 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17.09.2025 г., 18:14 ч. UTC

Пазарно говорене

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17.09.2025 г., 17:59 ч. UTC

Пазарно говорене

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17.09.2025 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17.09.2025 г., 17:06 ч. UTC

Придобивния, сливания и поглъщания

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17.09.2025 г., 16:51 ч. UTC

Печалби

Correct: Exor 1H Net Loss -EUR624M

17.09.2025 г., 16:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 16:34 ч. UTC

Пазарно говорене

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17.09.2025 г., 16:25 ч. UTC

Печалби

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17.09.2025 г., 16:23 ч. UTC

Печалби

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Сравнение с други в отрасъла

Ценова промяна

Amicus Therapeutics Inc Прогноза

Ценова цел

By TipRanks

101.87% нагоре

12-месечна прогноза

Среден 16.17 USD 101.87%

Висок 20 USD

Нисък 12 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Amicus Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Amicus Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.925 / 7.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

33 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.